MedPath

Insignia™ Hip Stem Outcomes Study

Not Applicable
Active, not recruiting
Conditions
Femoral Neck Fractures
Trochanteric Fractures
Rheumatoid Arthritis
Hip Osteoarthritis
Avascular Necrosis
Post-traumatic Osteoarthritis
Surgery
Registration Number
NCT05144191
Lead Sponsor
Stryker Orthopaedics
Brief Summary

The objective of this study is to evaluate the safety and effectiveness of the Insignia™ Hip Stem for global market access and post-market clinical follow-up up to 10 years postoperative.

Detailed Description

This study is a prospective, post-market, multi-center clinical investigation of the Insignia™ Hip Stem for primary and revision total hip arthroplasty (THA) in a consecutive series of patients who meet the eligibility criteria. The total enrollment goal for the study is a minimum of 313 cases, all of which will receive the Insignia™ Hip Stem.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
313
Inclusion Criteria
  • The subject has signed an Institutional Review Board (IRB)-approved, study specific Informed Consent Form (ICF).
  • The subject is skeletally mature
  • The subject has a diagnosis as listed in the instructions for use (IFU), which include non inflammatory degenerative joint disease (including osteoarthritis or avascular necrosis), rheumatoid arthritis or post-traumatic arthritis, correction of functional deformity, treatment of nonunion, femoral neck and trochanteric fractures.
  • The subject is a candidate for a primary or revision cementless THA.
  • The subject is willing and able to comply with postoperative scheduled clinical evaluations.
Exclusion Criteria
  • The subject is pregnant or breastfeeding
  • The subject has an active or suspected latent infection in or about the affected hip joint at the time of study device implantation.
  • The subject has any mental or neuromuscular disorder which would create an unacceptable risk of prosthesis instability, prosthesis fixation failure, or complications in postoperative care.
  • The subject has bone stock compromised by disease, infection or prior implantation which cannot provide adequate support and/or fixation to the prosthesis.
  • The subject is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. > 30 days).
  • The subject has a known sensitivity to device materials.
  • The subject is involved in any ongoing legal matter, investigation, or dispute pertaining to the operative site.
  • The subject is a prisoner.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Survival Rate10 years

Evaluation of the survival rate for Insignia Hip Stem is defined as absence of femoral stem revision for aseptic loosening or device-related femoral fracture.

Harris Hip Score (HHS)10 Years

The Harris Hip Score (HHS) assesses pain, function, joint deformity and range of motion.

Scores can range from 0 to 100 with 0 being the worst and 100 being the best score.

A score of 80-100 is considered good-excellent and a score of less than or equal to 79 is considered fair-poor. 90-100 = excellent 80-89 = good 70-79 = fair 0-69 = poor

Secondary Outcome Measures
NameTimeMethod
Harris Hip Score (HHS)pre-op, 6 week, 1,2,5 and 7 years

The Harris Hip Score (HHS) assesses pain, function, joint deformity and range of motion.

Scores can range from 0 to 100 with 0 being the worst and 100 being the best score.

A score of 80-100 is considered good-excellent and a score of less than or equal to 79 is considered fair-poor. 90-100 = excellent 80-89 = good 70-79 = fair 0-69 = poor

EQ-5D - Visual analogue scale (VAS)pre-op, 6 week, 1,2,3, 4,5,7 and 10 years

The EuroQol-5 Dimension (EQ-5D) is a subject-completed questionnaire designed to assess subject health state values.

With the EQ Visual Analogue Scale (VAS) the respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).

Survival Rate2 years

Evaluation of the survival rate for Insignia™ Hip Stem is defined as absence of femoral stem revision for aseptic loosening or device-related femoral fracture

Success rate at two (2) years postoperative with the Insignia™ Hip Stem is not worse than 98 % with a non-inferiority margin of 3.5%.

Success rate at 10 years postoperative with the Insignia™ Hip Stem is not worse than 95% with a non-inferiority margin of 5%.

EQ-5D - Descriptive Systempre-op, 6 week, 1,2,3, 4,5,7 and 10 years

The EuroQol-5 Dimension (EQ-5D) is a subject-completed questionnaire designed to assess subject health state values.

The EQ-5D descriptive system comprises the following five dimensions: mobility self care, usual activities, pain/comfort and anxiety/depression. Each dimension has 3 levels indicating no problems, some problems or extreme problems. The index values on a scale between -1 (low) and 1 (high) are showing the average health status according to the 5 dimensions: A low score shows worse health and a high score shows better health.

Trial Locations

Locations (11)

The MORE Foundation

🇺🇸

Phoenix, Arizona, United States

University of California, San Francisco

🇺🇸

San Francisco, California, United States

Midwest Orthopaedics at Rush

🇺🇸

Chicago, Illinois, United States

Reno Orthopedic Center Foundation

🇺🇸

Reno, Nevada, United States

Northwell Health: University Orthopaedic Associates

🇺🇸

Great Neck, New York, United States

OrthoCarolina Research Institute

🇺🇸

Charlotte, North Carolina, United States

Alleghany Health Network- Research Institute

🇺🇸

Pittsburgh, Pennsylvania, United States

TOA Research Foundation

🇺🇸

Nashville, Tennessee, United States

Baylor Scott and White Medical Center

🇺🇸

Temple, Texas, United States

Orthopedic Physician Associates

🇺🇸

Seattle, Washington, United States

Scroll for more (1 remaining)
The MORE Foundation
🇺🇸Phoenix, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.